Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapies
Open Access
- 12 February 2026
- journal article
- Published by Wiley in HemaSphere
- Vol. 10 (2)
Abstract
Prognosis in therapy‐related acute myeloid leukemia (T‐AML) remains poor, but understanding outcomes with venetoclax (VEN)‐based therapy is relevant. We retrospectively analyzed 317 adult patients with newly diagnosed T‐AML focusing on lower intensity therapy (LIT) VEN‐containing regimens. Patients with an antecedent myeloid disorder before AML diagnosis were excluded. The median age was 69 years (range 21–92); 50% evaluated patients had a complex karyotype, and 40% evaluated patients had a TP53 mutation. Composite complete response rates were higher with LIT + VEN compared to LIT (58% vs. 40%, P = 0.003) but were similar in intensive chemotherapy (IC) + VEN versus IC alone (68% vs. 61%, P = 0.59). Rates of allogeneic hematopoietic stem cell transplantation (HSCT) were higher in VEN‐treated patients: 22% versus 7% in LIT + VEN and LIT, and 64% versus 39% in IC + VEN and IC, respectively. At a median follow‐up of 46.4 months, the median relapse‐free survival (RFS) and overall survival (OS) of the full cohort were 7.2 and 8.4 months, respectively. Among LIT + VEN‐treated patients, the median RFS and OS were 8.0 and 9.0 months, respectively; in patients with ELN2024 favorable risk, the median OS was 25.4 months (1‐year OS rate of 62%), compared to 9.4 months in the intermediate ( FLT3 ‐ITD and/or RAS mutated) and 4.8 months in the adverse risk ( TP53 mutated) group. Patients with NPM1 and/or IDH mutations had 2‐year OS over 60%. On multivariate analysis in LIT + VEN‐treated patients, HSCT and NPM1 / IDH2 mutations were favorable, while TP53 / RAS mutations were associated with inferior survival. VEN‐based therapy improves outcomes in patients with T‐AML, especially in those with VEN‐sensitizing genomics and receiving an HSCT.Keywords
This publication has 40 references indexed in Scilit:
- Therapy-related myeloid neoplasms: when genetics and environment collideNature Reviews Cancer, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control studyThe Lancet Oncology, 2017
- Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort StudyJournal of Clinical Oncology, 2015
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008Blood, 2013
- The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AMLBlood, 2011
- Therapy‐related myeloid neoplasms: pathobiology and clinical characteristicsBritish Journal of Pharmacology, 2011
- Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyLeukemia, 2010
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago seriesBlood, 2003